Bicara Therapeutics Inc (NASDAQ: BCAX) started the day on Wednesday, with a price increase of 12.23% at $15.51, before settling in for the price of $13.82 at the close. Taking a more long-term approach, BCAX posted a 52-week range of $8.91-$28.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 0.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 56.70%. This publicly-traded company’s shares outstanding now amounts to $54.44 million, simultaneously with a float of $30.95 million. The organization now has a market capitalization sitting at $753.51 million. At the time of writing, stock’s 50-day Moving Average stood at $12.86.
Bicara Therapeutics Inc (BCAX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Bicara Therapeutics Inc’s current insider ownership accounts for 43.23%, in contrast to 55.47% institutional ownership. According to the most recent insider trade that took place on Mar 14 ’25, this organization’s Chief Legal Officer sold 79,146 shares at the rate of 12.90, making the entire transaction reach 1,021,211 in total value, affecting insider ownership by 0.
Bicara Therapeutics Inc (BCAX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.41 per share during the current fiscal year.
Bicara Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 56.70% and is forecasted to reach -2.27 in the upcoming year.
Bicara Therapeutics Inc (NASDAQ: BCAX) Trading Performance Indicators
Let’s observe the current performance indicators for Bicara Therapeutics Inc (BCAX). It’s Quick Ratio in the last reported quarter now stands at 27.93. The Stock has managed to achieve an average true range (ATR) of 1.50.
Technical Analysis of Bicara Therapeutics Inc (BCAX)
If we take a close look at the recent performances of Bicara Therapeutics Inc (NASDAQ: BCAX), its last 5-days Average volume was 0.64 million that shows progress from its year to date volume of 0.47 million. During the previous 9 days, stock’s Stochastic %D was recorded 91.63% While, its Average True Range was 1.57.
Raw Stochastic average of Bicara Therapeutics Inc (BCAX) in the period of the previous 100 days is set at 47.95%, which indicates a major fall in contrast to 90.29% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 118.22% that was higher than 85.37% volatility it exhibited in the past 100-days period.
